267 related articles for article (PubMed ID: 24131779)
1. A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies.
Nemunaitis JJ; Small KA; Kirschmeier P; Zhang D; Zhu Y; Jou YM; Statkevich P; Yao SL; Bannerji R
J Transl Med; 2013 Oct; 11():259. PubMed ID: 24131779
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies.
Mita MM; Mita AC; Moseley JL; Poon J; Small KA; Jou YM; Kirschmeier P; Zhang D; Zhu Y; Statkevich P; Sankhala KK; Sarantopoulos J; Cleary JM; Chirieac LR; Rodig SJ; Bannerji R; Shapiro GI
Br J Cancer; 2017 Oct; 117(9):1258-1268. PubMed ID: 28859059
[TBL] [Abstract][Full Text] [Related]
3. Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies.
Zhang D; Mita M; Shapiro GI; Poon J; Small K; Tzontcheva A; Kantesaria B; Zhu Y; Bannerji R; Statkevich P
Cancer Chemother Pharmacol; 2012 Dec; 70(6):891-8. PubMed ID: 23053255
[TBL] [Abstract][Full Text] [Related]
4. Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias.
Gojo I; Sadowska M; Walker A; Feldman EJ; Iyer SP; Baer MR; Sausville EA; Lapidus RG; Zhang D; Zhu Y; Jou YM; Poon J; Small K; Bannerji R
Cancer Chemother Pharmacol; 2013 Oct; 72(4):897-908. PubMed ID: 23949430
[TBL] [Abstract][Full Text] [Related]
5. Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients.
Fabre C; Gobbi M; Ezzili C; Zoubir M; Sablin MP; Small K; Im E; Shinwari N; Zhang D; Zhou H; Le Tourneau C
Cancer Chemother Pharmacol; 2014 Nov; 74(5):1057-64. PubMed ID: 25217392
[TBL] [Abstract][Full Text] [Related]
6. A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer.
Mitri Z; Karakas C; Wei C; Briones B; Simmons H; Ibrahim N; Alvarez R; Murray JL; Keyomarsi K; Moulder S
Invest New Drugs; 2015 Aug; 33(4):890-4. PubMed ID: 25947565
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer.
Mita MM; Joy AA; Mita A; Sankhala K; Jou YM; Zhang D; Statkevich P; Zhu Y; Yao SL; Small K; Bannerji R; Shapiro CL
Clin Breast Cancer; 2014 Jun; 14(3):169-76. PubMed ID: 24393852
[TBL] [Abstract][Full Text] [Related]
8. Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia.
Flynn J; Jones J; Johnson AJ; Andritsos L; Maddocks K; Jaglowski S; Hessler J; Grever MR; Im E; Zhou H; Zhu Y; Zhang D; Small K; Bannerji R; Byrd JC
Leukemia; 2015 Jul; 29(7):1524-9. PubMed ID: 25708835
[TBL] [Abstract][Full Text] [Related]
9. Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma.
Kumar SK; LaPlant B; Chng WJ; Zonder J; Callander N; Fonseca R; Fruth B; Roy V; Erlichman C; Stewart AK;
Blood; 2015 Jan; 125(3):443-8. PubMed ID: 25395429
[TBL] [Abstract][Full Text] [Related]
10. Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors.
Dolly SO; Wagner AJ; Bendell JC; Kindler HL; Krug LM; Seiwert TY; Zauderer MG; Lolkema MP; Apt D; Yeh RF; Fredrickson JO; Spoerke JM; Koeppen H; Ware JA; Lauchle JO; Burris HA; de Bono JS
Clin Cancer Res; 2016 Jun; 22(12):2874-84. PubMed ID: 26787751
[TBL] [Abstract][Full Text] [Related]
11. A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors.
Massard C; Soria JC; Anthoney DA; Proctor A; Scaburri A; Pacciarini MA; Laffranchi B; Pellizzoni C; Kroemer G; Armand JP; Balheda R; Twelves CJ
Cell Cycle; 2011 Mar; 10(6):963-70. PubMed ID: 21368575
[TBL] [Abstract][Full Text] [Related]
12. Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program.
Gorlick R; Kolb EA; Houghton PJ; Morton CL; Neale G; Keir ST; Carol H; Lock R; Phelps D; Kang MH; Reynolds CP; Maris JM; Billups C; Smith MA
Pediatr Blood Cancer; 2012 Dec; 59(7):1266-74. PubMed ID: 22315240
[TBL] [Abstract][Full Text] [Related]
13. Dinaciclib for the treatment of breast cancer.
Criscitiello C; Viale G; Esposito A; Curigliano G
Expert Opin Investig Drugs; 2014 Sep; 23(9):1305-12. PubMed ID: 25107301
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer.
Stephenson JJ; Nemunaitis J; Joy AA; Martin JC; Jou YM; Zhang D; Statkevich P; Yao SL; Zhu Y; Zhou H; Small K; Bannerji R; Edelman MJ
Lung Cancer; 2014 Feb; 83(2):219-23. PubMed ID: 24388167
[TBL] [Abstract][Full Text] [Related]
15. Pro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia.
Chen Y; Germano S; Clements C; Samuel J; Shelmani G; Jayne S; Dyer MJ; Macip S
Br J Haematol; 2016 Nov; 175(4):641-651. PubMed ID: 27469405
[TBL] [Abstract][Full Text] [Related]
16. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor.
Parry D; Guzi T; Shanahan F; Davis N; Prabhavalkar D; Wiswell D; Seghezzi W; Paruch K; Dwyer MP; Doll R; Nomeir A; Windsor W; Fischmann T; Wang Y; Oft M; Chen T; Kirschmeier P; Lees EM
Mol Cancer Ther; 2010 Aug; 9(8):2344-53. PubMed ID: 20663931
[TBL] [Abstract][Full Text] [Related]
17. A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer.
Lin SF; Lin JD; Hsueh C; Chou TC; Wong RJ
PLoS One; 2017; 12(2):e0172315. PubMed ID: 28207834
[TBL] [Abstract][Full Text] [Related]
18. Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial.
Papadopoulos KP; Ben-Ami E; Patnaik A; Trone D; Li J; Demetri GD
BMC Cancer; 2018 Aug; 18(1):790. PubMed ID: 30081867
[TBL] [Abstract][Full Text] [Related]
19. Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours.
Boss DS; Schwartz GK; Middleton MR; Amakye DD; Swaisland H; Midgley RS; Ranson M; Danson S; Calvert H; Plummer R; Morris C; Carvajal RD; Chirieac LR; Schellens JHM; Shapiro GI
Ann Oncol; 2010 Apr; 21(4):884-894. PubMed ID: 19825886
[TBL] [Abstract][Full Text] [Related]
20. A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors.
Mahadevan D; Plummer R; Squires MS; Rensvold D; Kurtin S; Pretzinger C; Dragovich T; Adams J; Lock V; Smith DM; Von Hoff D; Calvert H
Ann Oncol; 2011 Sep; 22(9):2137-2143. PubMed ID: 21325451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
